Noven Pharmaceuticals (NOVN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Noven Pharmaceuticals (NOVN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zizzerzazzer who wrote (49)	8/5/1999 2:13:00 PM
From: zizzerzazzer	Read Replies (1) of 66

Great Quarter & Conference Call Don't see how NOVN could have done much better. Conference call was upbeat. Unfortunately, only three questioners - Fahnestock, Volpe Brown and PPL(?) Not sure who PPL is. Fahnestock and Volpe Brown have probabty already reached most of their universe of investors. Was hoping to see some new institutional interest, but it doesn't yet appear to be there. Highlights of the conference call, IMHO, were: Combipatch and Vivelle.dot be well received. Pricing has been at the upper end of expectations. Both products recently featured on Lifetime's New Attitudes program. Vivelle family has picked up 2% in market share in the past two months. 20 Products in the pipeline. Strauss talked quite a bit about the Ritalin Patch. Expect NDA on this in 2001. 2nd Half earnings expected to be "at least" as profitable as 1st Half. NOVN's strength is the underlying unique and proprietary technology. Unaware of any competitive threats to Combipatch on the horizon. Again, everything seems upbeat, we just need to attract more institutional interest or perhaps a acquirer to the stock. Any other thoughts or comments? GLTA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next